IOL Chemicals & Pharmaceuticals Limited has disclosed that its promoter group entity, Mayadevi Polycot Limited, has increased its shareholding in the company through an on-market acquisition. The transaction, completed on March 18, 2026, was disclosed under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015.

Latest Transaction Details

The recent shareholding acquisition involved a purchase of equity shares by Mayadevi Polycot Limited on March 18, 2026:

Updated Shareholding Position

The acquisition has resulted in an increase in Mayadevi Polycot Limited's individual stake in IOL Chemicals and Pharmaceuticals Limited:

The increase of 0.02 percentage points in shareholding reflects the promoter group entity's continued investment in the company.

Regulatory Compliance and Disclosure

The disclosure was made in accordance with Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. IOL Chemicals and Pharmaceuticals Limited communicated this information to both the National Stock Exchange of India Limited (NSE) and BSE Limited on March 19, 2026.

Company Structure

Mayadevi Polycot Limited is classified as a promoter group entity of IOL Chemicals and Pharmaceuticals Limited. The entity is based at 86 Industrial Area A, Ludhiana. The disclosure was signed by Varinder Gupta, Director of Mayadevi Polycot Limited, and countersigned by Abhay Raj Singh, Sr. Vice President & Company Secretary of IOL Chemicals and Pharmaceuticals Limited.

The transaction represents a strategic investment by the promoter group entity, demonstrating continued confidence in the company's prospects and reinforcing their commitment to the company's growth trajectory.

IOL Chemicals & Pharmaceuticals has secured an important regulatory milestone with the European Directorate for the Quality of Medicines & Health Care (EDQM) granting a Certificate of Suitability (CEP) for its API product Metformin Hydrochloride Process-II. This achievement expands the company's regulatory portfolio for this critical antidiabetic medication.

Regulatory Certification Details

The EDQM certification represents a significant regulatory approval for IOL Chemicals & Pharmaceuticals' manufacturing processes. The company disclosed that this new CEP comes in addition to an existing valid certificate already held for Metformin Hydrochloride, indicating the company now has multiple approved processes for manufacturing this important pharmaceutical ingredient.

Product Significance

Metformin Hydrochloride serves as a crucial antidiabetic drug used to manage high blood sugar levels in diabetes patients. The availability of multiple certified manufacturing processes for this API demonstrates IOL Chemicals & Pharmaceuticals' commitment to ensuring reliable supply and manufacturing flexibility for this essential medication.

Regulatory Compliance

The company announced this development in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure ensures transparency with stakeholders and regulatory authorities regarding this significant regulatory achievement.

Strategic Impact

This additional EDQM certification strengthens IOL Chemicals & Pharmaceuticals' position in the pharmaceutical API market, particularly for diabetes management medications. Having multiple approved processes for Metformin Hydrochloride production provides the company with enhanced manufacturing capabilities and regulatory compliance across European markets.